Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


22 Items
Title  Creator  Group name  Publishing year 
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells Slaninová et al. EquipeAD 2024-05-14
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells Cherradi et al. EquipeMY 2023-04-11
Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells Denis et al. PlateformePP2I 2022
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry Vezzio-Vié et al. EquipeCTCS 2022-05-20
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1 Matheux et al. EquipeCG 2021-07-20
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells Corvaglia et al. EquipeCG 2021-06-28
BAG6 promotes PINK1 signaling pathway and is essential for mitophagy Ragimbeau et al. EquipeCG 2021-02
Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time Fohlen et al. EquipeCG 2021-07-01
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor Creusot et al. EquipeCG 2020-07-08
Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems Re?nik et al. EquipeCG 2020-11-15
Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype Cherradi et al. EquipePM 2019
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer Ogier et al. EquipeAP 09 28, 2018
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection Viala et al. EquipeCG Mar 06, 2018
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment Tosi et al. EquipePM Aug 13, 2018
The epigenetic factor PCAF regulates vascular inflammation and is essential for intimal hyperplasia development de Jong et al. EquipeCG 2017
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Klionsky et al. EquipeAT 2016
Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells Bach et al. EquipeELC Sep 29, 2015
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeELC Aug 30, 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeAP Aug 30, 2014
BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy Sebti et al. PlateformeRHEM Mar 18, 2014
BAG6/BAT3 modulates autophagy by affecting EP300/p300 intracellular localization Sebti et al. EquipeELC Jul 2014
22 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés